Becker's ASC

The potential to be 1st — Dr. William Chey on Ritter Pharmaceuticals’ lactose intolerance treatment

Becker’s ASC Review spoke with William Chey, MD, of Ritter Pharmaceuticals’ medical advisory board, about the first treatment for lactose intolerance, the company’s RP-G28. The treatment has not yet ...
Healio

Novel prebiotic shows promise in lactose intolerance

Please provide your email address to receive an email when new articles are posted on . Patients with lactose intolerance who received RP-G28, a high purity short-chain galactooligosaccharide ...
Nasdaq

Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance

LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate ...
Monthly Prescribing Reference

Investigational Lactose Intolerance Therapy Misses End Points in Phase 3 Trial

Ritter Pharmaceuticals announced that the phase 3 clinical trial of RP-G28 for lactose intolerance did not meet its primary or secondary end points. Ritter Pharmaceuticals announced that the phase 3 ...
Business Insider

Dr. William Chey Highlights Unmet Medical Need of Lactose Intolerance and Potential for Phase 3 Drug Candidate RP-G28 in Expert Call Hosted by Ritter Pharmaceuticals

LOS ANGELES, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the ...
Healio

Novel prebiotic shows continued reductions in lactose intolerance symptoms

Please provide your email address to receive an email when new articles are posted on . RP-G28, a novel non-digestible oligosaccharide designed to stimulate the gut microbiota to metabolize lactose, ...
Business Insider

Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance

LOS ANGELES, May 22, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut ...
Reuters

Ritter Pharmaceuticals Reports Microbiome Data From Phase 2B Study Of RP-G28 Promotes Beneficial Adaptation Of The Gut Microbiome

* RITTER PHARMACEUTICALS INC - ‍DURING PHASE 2A STUDY, OBSERVED AN INCREASE IN BIFIDOBACTERIA, WHICH WERE CONFIRMED IN LARGER PHASE 2B STUDY * RITTER PHARMACEUTICALS INC - ‍PHASE 3 CLINICAL TRIAL OF ...
BioWorld

Ritter struggles as its lead candidate fails phase III trial in lactose intolerance

Ritter Pharmaceuticals Inc. is reeling from the phase III failure of its lead candidate, RP-G28, designed for patients with lactose intolerance. RP-G28 failed to demonstrate statistical significance ...
technologynetworks

Ritter Completes Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance

Ritter Pharmaceuticals, Inc. (Ritter) has announced the last patient has completed treatment in its Phase 2 study for RP-G28, a first-in-class treatment for symptoms associated with lactose ...
Nasdaq

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update

In September 2019, the Company announced that its Phase 3 clinical trial of RP-G28 for lactose intolerance (LI), known as “Liberatus,” failed to demonstrate statistical significance in its ...
Reuters

Ritter Pharmaceuticals announces issuance of new patents for its lactose intolerance treatment, RP-G28

U.S. gas exporters are asking Europe to delay the enforcement of a new methane emissions law until 2028, a top official of the national suppliers' lobby said on Tuesday, ‌warning the regulatory risk ...